Recent studies on anticancer therapy targeting RCC have mainly focused on inhibitors of vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways [2]. The gene discussed is VEGFA; the disease is renal cell carcinoma.